Appropriate choice of proton pump inhibitor therapy in the prevention and management of NSAID-related gastrointestinal damage

International Journal of Clinical Practice

Volumn 59, Issue 10, 2005, Pages 1210-1217

  Singh, G ^a   Triadafilopoulos, G ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Gastrointestinal toxicity; Non steroidal anti inflammatory drugs; Pantoprazole; Prophylaxis; Proton pump inhibitors

Indexed keywords

ACETYLSALICYLIC ACID; AMOXICILLIN PLUS CLAVULANIC ACID; ANTICOAGULANT AGENT; ANTIHISTAMINIC AGENT; CARBAMAZEPINE; CELECOXIB; CORTICOSTEROID DERIVATIVE; CYCLOOXYGENASE 1; CYTOCHROME P450 2C9; DIAZEPAM; DICLOFENAC; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; MISOPROSTOL; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PANTOPRAZOLE; PARACETAMOL; PHENYTOIN; PIROXICAM; PLACEBO; PROSTAGLANDIN DERIVATIVE; PROTON PUMP INHIBITOR; RANITIDINE; ROFECOXIB; UNINDEXED DRUG; VALDECOXIB; WARFARIN; 2 [[(2 PYRIDYL)METHYL]SULFINYL]BENZIMIDAZOLE DERIVATIVE; ANTIULCER AGENT; BENZIMIDAZOLE DERIVATIVE; DRUG DERIVATIVE; PROTON PUMP; SULFOXIDE;

ABDOMINAL CRAMP; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COLON DISEASE; DIARRHEA; DIGESTIVE SYSTEM INJURY; DIGESTIVE SYSTEM PERFORATION; DIZZINESS; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DUODENUM DISEASE; DUODENUM ULCER; DYSPEPSIA; EROSIVE GASTRITIS; GASTRODUODENAL ULCER; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; GERIATRIC PATIENT; HEADACHE; HEALING; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; ILEUM DISEASE; INTESTINE ULCER; JEJUNUM ULCER; MUCOSAL DISEASE; PATIENT COMPLIANCE; PEPTIC ULCER; PRIMARY PREVENTION; PRIORITY JOURNAL; PRURITUS; RECURRENT DISEASE; REVIEW; RHEUMATIC DISEASE; SECONDARY PREVENTION; SIDE EFFECT; SMALL INTESTINE PERFORATION; STOMACH EROSION; STOMACH ULCER; STROKE; SUDDEN DEATH; ULCER HEALING; UPPER GASTROINTESTINAL BLEEDING; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTI-ULCER AGENTS; BENZIMIDAZOLES; HUMANS; OMEPRAZOLE; PEPTIC ULCER; PROTON PUMPS; SULFOXIDES;

EID: 33644843795     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1368-5031.2005.00660.x     Document Type: Review

References (64)

1. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. N Engl J Med 1999; 340: 1888-99.
2. Lee M, Feldman M. The aging stomach: Implications for NSAID gastropathy. Gut 1997; 41: 425-6.
3. Smalley WE, Griffin MR, Fought RL, Ray WA. Excess costs from gastrointestinal disease associated with nonsteroidal anti-inflammatory drugs. J Gen Intern Med 1996; 11: 461-9.
4. Stalnikowicz R, Rachmilewitz D. NSAID-induced gastroduodenal damage: Is prevention needed? A review and metaanalysis. J Clin Gastroenterol 1993; 17: 238-43.
5. Fries JF, Miller SR, Spitz PW et al. Identification of patients at risk for gastropathy associated with NSAID use. J Rheumatol 1990; 20: 12-9.
6. Silverstein FE, Graham DY, Senior JR et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs: A randomised, double-blind, placebo-controlled trial. Ann Intern Med 1995; 123: 241-9.
7. Singh G, Ramey DR, Morfeld D et al. Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis: A prospective observational cohort study. Arch Intern Med 1996; 156: 1530-6.
8. Hernandez-Diaz S, Rodriguez LA. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/ perforation: An overview of epidemiologic studies published in the 1990s. Arch Intern Med 2000; 160: 2093-9.
9. Armstrong CP, Blower AL. Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration. Gut 1987; 28: 527-32.
10. Smale S, Tibble J, Sigthorsson G, Bjarnason I. Epidemiology and differential diagnosis of NSAID-induced injury to the mucosa of the small intestine. Best Pract Res Clin Gastroenterol 2001; 15: 723-38.
11. Schneider AR, Benz C, Riemann JF. Adverse effects of non-steroidal anti-inflammatory drugs on the small and large bowel. Endoscopy 1999; 31: 761-7.
12. Allison MC, Howatson AG, Torrance CJ et al. Gastrointestinal damage associated with the use of non-steroidal anti-inflammatory drugs. N Engl J Med 1992; 327: 749-54.
13. Chutkan R, Toubia N. Effect of nonsteroidal anti-inflammatory drugs on the gastrointestinal tract: Diagnosis by wireless capsule endoscopy. Gastrointest Endosc Clin N Am 2004; 14: 67-85.
14. Graham DY, Opekun AR, Willingham FF, Qureshi WA. Visible small-intestinal mucosal injury in chronic NSAID users. Clin Gastroenterol Hepatol 2005; 3: 55-9.
15. Lanza FL. A guideline for the treatment and prevention of NSAID-induced ulcers. Am J Gastroenterol 1998; 93: 2037-46.
16. Chan FKL, To KF, Wu JCY et al. Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: A randomised trial. Lancet 2002; 359: 9-13.
17. Bianchi Porro G, Parente F, Imbesi V et al. Role of Helicobacter pylori in ulcer healing and recurrence of gastric and duodenal ulcers in long-term NSAID users: Response to omeprazole dual therapy. Gut 1996; 39: 22-6.
18. Lai KC, Lau CS, Ip WY et al. Effect of treatment of Helicobacter pylori on the prevention of gastroduodenal ulcers in patients receiving long-term NSAIDs: A double-blind, placebo-controlled trial. Aliment Pharmacol Ther 2003; 17: 799-805.
19. Bannwarth B, Dorval E, Caekaert A, Barthelemy P. Influence of Helicobacter pylori eradication therapy on the occurrence of gastrointestinal events in patients treated with conventional nonsteroidal antiinflammatory drugs combined with omeprazole. J Rheumatol 2002; 29: 1975-80.
20. Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic ulcer disease: A meta-analysis. Lancet 2002; 359: 14-22.
21. Hawkey CJ, Tulassay Z, Szczepanski L et al. Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Lancet 1998; 352: 1016-21.
22. Micklewright R, Lane S, Linley W et al. Review article: NSAIDs, gastroprotection and cyclo-oxygenase-II-selective inhibitors. Aliment Pharmacol Ther 2003; 17: 321-32.
23. Bombardier C, Laine L, Reicin A et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 343: 1520-8.
24. Goldstein JL, Eisen GM, Lewis B et al. Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole and placebo. Clin Gastroenterol Hepatol 2005; 3: 133-41.
25. Solomon DH, Schneeweiss S, Glynn RJ et al. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 2004; 109: 2068-73.
26. Juni P, Nartey L, Reichenbach S et al. Risk of cardiovascular events and rofecoxib: Cumulative meta-analysis. Lancet 2004; 364: 2021-9.
27. Porter V. NSAIDs still under surveillance -celecoxib, valdecoxib and naproxen have been added to the list of suspects. Medscape Cardiol 2005; 9 (1). Retrieved from http://www.medscape.com/viewarticle/496951?rss.
28. National Cancer Institute. Press release: NIH halts use of COX-2 inhibitor in large cancer prevention trial. 17 December 2004 Retrieved from http://www.nci.nih.gov/newscenter/pressreleases/APCtrialCOX2.
29. Ray WA, Griffin MR, Stein CM. Cardiovascular toxicity of valdecoxib. N Engl J Med 2004; 351: 2767.
30. Weil J, Colin-Jones D, Langman M et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ 1995; 310: 827-30.
31. Goldstein JL, Gibofsky A, Fort JG. Incidence of endoscopic gastroduodenal ulcers in subjects on 325 mg qd of aspirin for cardiovascular prophylaxis with placebo, a COX-2 specific inhibitor, or a nonspecific NSAID: Results from a randomized, double-blind, controlled trial [Poster LB14/523]. Presented at the American College of Rheumatology Annual Meeting, Orlando, USA, 23-28 October 2003.
32. Graham DY, Agrawal NM, Campbell DR et al. Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: Results of a double-blind randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazole. Arch Intern Med 2002; 162: 169-75.
33. Chan FK, Sung JJ, Ching JY et al. Randomized trial of low-dose misoprostol and naproxen vs nabumetone to prevent recurrent upper gastrointestinal hemorrhage in users of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2001; 15: 19-24.
34. Hawkey CJ, Karrasch JA, Szczepanski L et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. N Engl J Med 1998; 338: 727-34.
35. Agrawal NM, Van KE, Erhardt LJ, Geis GS. Misoprostol co-administered with diclofenac for prevention of gastroduodenal ulcers. A one-year study. Dig Dis Sci 1995; 40: 1125-31.
36. Raskin JB, White RH, Jackson JE et al. Misoprostol dosage in the prevention of nonsteroidal anti-inflammatory drug-induced gastric and duodenal ulcers: A comparison of three regimens. Ann Intern Med 1995; 123: 344-50.
37. Rostom A, Dube C, Wells G et al. Prevention of NSAID-induced gastroduodenal ulcers (Cochrane Review). In: The Cochrane Library Issue 2. Oxford: Update Software, 2003.
38. Taha AS, Hudson N, Hawkey CJ et al. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal anti-inflammatory drugs. N Engl J Med 1996; 334: 1435-9.
39. Simon B, Muller P. Nizatidine in therapy and prevention of non-steroidal anti-inflammatory drug-induced gastroduodenal ulcer in rheumatic patients. Scand J Gastroenterol 1994; 206: 25-8.
40. Levine LR, Cloud ML, Enas NH. Nizatidine prevents peptic ulceration in high-risk patients taking nonsteroidal anti-inflammatory drugs. Arch Intern Med 1993; 153: 2449-54.
41. Swift GL, Heneghan M, Williams GT et al. Effect of ranitidine on gastroduodenal mucosal damage in patients on long-term non-steroidal anti-inflammatory drugs. Digestion 1989; 44: 86-94.
42. Ehsanullah RSB, Page MC, Tildesley G et al. Prevention of gastroduodenal damage induced by non-steroidal anti-inflammatory drugs: Controlled trial of ranitidine. BMJ 1988; 297: 1017-21.
43. Cheer SM, Prakash A, Faulds D, Lamb HM. Pantoprazole: An update of its pharmacological properties and therapeutic use in the management of acid-related disorders. Drugs 2003; 63: 101-33.
44. Müller P, Simon B. The action of the proton pump inhibitor pantoprazol against acetylsalicylic acid-induced gastroduodenopathy in comparison to ranitidine. An endoscopic controlled double blind comparison. Arzneimittelforschung 1998; 48: 482-5 (Article in German).
45. Cullen D, Bardhan KD, Eisner M et al. Primary gastroduodenal prophylaxis with omeprazole for non-steroidal anti-inflammatory drug users. Aliment Pharmacol Ther 1998; 12: 135-40.
46. Ekstrom P, Carling L, Wetterhus S et al. Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal anti-inflammatory drug therapy. A Nordic multicentre study. Scand J Gastroenterol 1996; 31: 753-8.
47. Bianchi Porro G, Lazzaroni M, Imbresi V et al. Efficacy of pantoprazole in the prevention of peptic ulcers, induced by non-steroidal anti-inflammatory drugs: A prospective, placebo-controlled, double-blind, parallel-group study. Dig Liver Dis 2000; 32: 201-8.
48. Stupnicki T, Dietrich K, Gonzalez-Carro P et al. Efficacy and tolerability of pantoprazole compared with misoprostol for prevention of NSAID-related gastrointestinal lesions and symptoms in rheumatic patients. Digestion 2003; 68: 198-208.
49. Regula J, Deckers CPM, Raps D et al. Comparison of 20 mg and 40 mg pantoprazole vs 20 mg omeprazole in the prevention of the development of gastrointestinal lesions in rheumatic patients with continuous NSAID intake. Gut 2001; 49 (Suppl. III): A1229 (Abstract).
50. Pilotto A, Di Mario F, Franceschi M et al. Pantoprazole versus one-week Helicobacter pylori eradication therapy for the prevention of acute NSAID-related gastroduodenal damage in elderly subjects. Aliment Pharmacol Ther 2000; 14: 1077-82.
51. Yeomans ND, Tulassay Z, Juhasz L et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal anti-inflammatory drugs. N Engl J Med 1998; 338: 719-26.
52. Olteanu D, Balan C, Andronescu A et al. Efficacy of pantoprazole as compared to omeprazole and misoprostol in NSAID associated gastric ulcer. Gut 2000; 47 (Suppl. III): A82 (Abstract).
53. Kujundzic M, Ljubicic N, Banic M et al. The frequency of relapse and bleeding previous gastroduodenal lesions in NSAID-users on maintenance treatment. Gut 2000; 47 (Suppl. III): A84 (Abstract).
54. Chan FKL, Hung LCT, Suen BY et al. Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: Results of a randomised double-blind trial. Gastroenterology 2004; 127: 1038-43.
55. Labenz J, Petersen KU, Rosch W, Koelz HR. A summary of food and drug administration-reported adverse events and drug interactions occurring during therapy with omeprazole, lansoprazole and pantoprazole. Aliment Pharmacol Ther 2003; 17: 1015-9.
56. Hahn EG, Erlangen H, Bosseckert J et al. Tolerability and safety profile of pantoprazole based on 100,134 patients. Results of a German post-marketing surveillance (PMS) program. Gastroenterology 1997; 112 (Suppl. 4): A138 (Abstract).
57. Gerson LB, Triadafilopoulos G. Proton pump inhibitors and their drug interactions: An evidence-based approach. Eur J Gastroenterol Hepatol 2001; 13: 611-6.
58. Steinijans VW, Huber R, Hartmann M et al. Lack of pantoprazole drug interactions in man: An updated review. Int J Clin Pharmacol Ther 1996; 34: 243-62.
59. Bliesath H, Hartmann M, Maier J et al. Lack of interaction between pantoprazole and piroxicam in man. Gut 2000; 47 (Suppl. III): A85 (Abstract).
60. Schulz HU, Hartmann M, Krupp S. Pantoprazole lacks interaction with the NSAID naproxen. Gastroenterology 2000; 118 (Suppl. 2): A1304 (Abstract).
61. Bliesath H, Huber R, Steinijans VW et al. Lack of pharmacokinetic interaction between pantoprazole and diclofenac. Int J Clin Pharmacol Ther 1996; 34: S76-S80.
62. Zech K, Steinijans VW, Huber R et al. Pharmacokinetics and drug interactions -relevant factors for the choice of a drug. Int J Clin Pharmacol Ther 1996; 34 (Suppl. 1): S3-S6.
63. Radhofer-Welte S. Pharmacokinetics and metabolism of the proton pump inhibitor pantoprazole in man. Drugs Today (Barc) 1999; 35: 765-72.
64. Moss SF, Armstrong D, Arnold R et al. GERD 2003-a consensus on the way ahead. Digestion 2003; 67: 111-7.